STRO Projected Dividend Yield
Sutro Biopharma Inc ( NASDAQ : STRO )Sutro Biopharma is a clinical-stage oncology company developing site-specific and antibody drug conjugates (ADCs) enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF®, and its site-specific conjugation platform, XpressCF+®. Co.'s product candidate is STRO-002, or luveltamab tazevibulin, an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. Co.'s other product candidate is STRO-001, an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Co. also has a preclinical product candidate, STRO-003, which is a single homogeneous ADC. 20 YEAR PERFORMANCE RESULTS |
STRO Dividend History Detail STRO Dividend News STRO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |